Predictive Oncology (NASDAQ: POAI), a data and
artificial-intelligence- (“AI”) driven, discovery-services company that
provides predictive models of tumor drug response to improve clinical outcomes
for patients, recently issued an update regarding its groundbreaking
CancerQuest 2020 initiative driven by its Helomics subsidiary (http://ibn.fm/gs5Qh). Per the
update, the company intends to have its first predictive model of ovarian
cancer prepared for initial commercialization in the first quarter of 2020. An
article discussing the company reads, “‘We believe that this effort will
enhance our understanding of the molecular profiles of women with ovarian
cancer by using the power of artificial intelligence to create predictive
models of therapeutic success,’ said Dr. Robert Edwards, professor and chair of
the Department of Obstetrics, Gynecology and Reproductive Sciences in the
University of Pittsburgh School of Medicine (http://ibn.fm/I7qrx). ‘We are excited about the potential
for AI-powered, evidence-based decision-making to increase our ability to bring
about successful outcomes.’ . . . In addition, Helomics intends to sequence 50%
of its 38,000-plus ovarian tumors in the upcoming year, creating what may be
the world’s first comprehensive, actionable multi-omic data set for ovarian
cancer. And Helomics doesn’t plan on stopping there. The company is already
evaluating ways to sequence other cancers types in its database to build
additional AI-driven predictive models, strengthening the company’s presence in
both the clinical and research markets.”
To view the full article, visit http://ibn.fm/I2ryk
About Predictive Oncology Inc.
Predictive Oncology operates through five segments
(domestic, international, clinical, CRO and D-CHIP), which contain four subsidiaries;
Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies
artificial intelligence to its rich data gathered from patient tumors to both
personalize cancer therapies for patients and drive the development of new
targeted therapies in collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists oncologists in
individualizing patient-treatment decisions, by providing an evidence-based
road map for therapy. In addition to its proprietary precision-oncology
platform, Helomics offers boutique CRO services that leverage its TruTumor(TM),
patient-derived tumor models coupled to a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics
platform (D- CHIP) to provide a tailored solution to its clients’ specific
needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid
approach to growing tumors in the laboratory, which essentially “fools” cancer
cells into thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform kits will assist researchers and
clinicians in identifying which cancer cells bind to specific biomarkers. Once
the biomarkers are identified, they can be used in TumorGenesis’ Oncology
Capture Technology Platforms, which isolate and help categorize an individual
patient’s heterogeneous tumor samples to enable the development of
patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian
cancer. Predictive Oncology’s Skyline Medical division markets its patented and
FDA-cleared STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and others, within a
medical facility, through both domestic and international divisions. The
company has achieved sales in five of the seven continents through both direct
sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
